Alice announced that the company recently received a letter from the FDA agreeing to use the self-developed injectable AST1001 to conduct clinical trials on adult patients with locally advanced or metastatic solid tumors who have previously failed standard treatment, IND number 183542. This study is a global multi-center, open-label, dose escalation, and dose expansion phase I clinical trial.

Alice announced that the company recently received a letter from the FDA agreeing to use the self-developed injectable AST1001 to conduct clinical trials on adult patients with locally advanced or metastatic solid tumors who have previously failed standard treatment, IND number 183542. This study is a global multi-center, open-label, dose escalation, and dose expansion phase I clinical trial.